9月1日，梅奥医学中心（Mayo Clinic）、Hibiscus BioVentures （Hibiscus）和健新原力（Innoforce）宣布启动“五月花生物科技”（简称：五月花）项目，该细胞与基因治疗加速器致力于发现和创建能够满足患者需求的技术公司。此学术和产业界的紧密联系将建立众多独立的细胞和基因治疗公司，并通过临床前和早期可行性研究，推动梅奥医学中心技术的发展。

以寻找治疗方法和预防疾病为共同目标，五月花旨在通过细胞和基因疗法大力推进对重症和复杂疾病新型疗法的开发。

梅奥医学中心连续七年蝉联《美国新闻与世界报道》发布的全美最佳医院排行榜榜首，已经开发下一代免疫系统调节剂和多种新型细胞与基因治疗疗法的强大产品组合。梅奥医学中心的再生医学中心（Center for Regenerative Medicine） 正在引领加速推动再生医学技术从研发到早期临床试验的发展，包括专注于与Hibiscus等公司的产业合作。梅奥医学中心利用这些公司的资源为项目提供支持，推动发展进程。

来自梅奥医学中心-再生医学中心的Michael S. 及Mary Sue Shannon家族总监Julie Allickson博士强调：“梅奥医学中心致力于为下一代新型疗法的开发、生产和交付构建一个先进的生态系统。”她表示：“细胞与基因疗法有望开创生物药新时代，为那些有极少或没有治疗选择的病患带来希望。我们非常高兴能与Hibiscus合作，加速新型生物疗法的开发。”

Allickson博士同时也担任再生医学中心生物制造与产品开发部门旗下Otto Bremer Trust的总监。

健新原力美国公司总裁Ken Carter博士表示：“与梅奥医学中心及Hibiscus的合作为加速细胞和基因疗法的开发提供了强大的平台。我们很高兴能与这两个卓越的机构合作，继续以合作伙伴的模式为先进药物开发建立端到端解决方案。”

Hibiscus BioTechnology首席运营官Sia Anagnostou女士进一步阐述：“我们与梅奥医学中心的合作代表了独特的研发与产业界的联盟。我们拥有共同的使命，为细胞与基因治疗的推进创建巨大的推动力。”她表示：“我们将利用梅奥医学中心的研究能力，致力解决大量尚未满足的病患需求，共同为新创业公司迈向成功提供跳板。”

五月花管理团队汇集来自梅奥医学中心的临床负责人以及具有运营和投资经验的Hibiscus团队，致力将科学发现从实验室送达患者床边。

梅奥医学中心风险投资公司（Mayo Clinic Ventures）主席Andrew Danielsen先生说道：“我们相信，这一合作能够弥合产业界与新型细胞和基因治疗研究之间的鸿沟，帮助新兴初创公司应对挑战，创造有意义且新颖的治疗方法，改变健康和医学领域。”

梅奥医学中心、Hibiscus和健新原力共同投资五月花合作项目。梅奥医学中心将利用获得的收入支持其在患者护理、教育和研究领域的非营利性使命。

关于梅奥医学中心

梅奥医学中心是一家非营利组织，致力于临床实践、教育和研究领域的创新，为所有需要治疗的病患提供富有同理心的护理、专业知识和解决方案。欲了解更多关于梅奥医学中心的讯息，请访问梅奥医学中心新闻网（Mayo Clinic News Network）。

关于梅奥医学中心再生医学中心

梅奥医学中心再生医学中心力求整合、开发和部署新型再生医学产品和服务，持续突出梅奥独特属性，吸引世界各地的患者进行综合保健。欲了解更多信息，请访问梅奥医学中心的再生医学中心网站：Center for Regenerative Medicine website。

关于 Hibiscus BioVentures

Hibiscus BioVentures (Hibiscus)通过建立以患者为中心的公司，围绕变革性技术和开发商业可行疗法，推进患者护理发展。Hibiscus拥有两个运营子公司：Hibiscus Biotechnology有限责任公司（HBT）和Hibiscus Capital Management有限责任公司（HCM）。前者侧重从零开始创建公司；后者是专注投资具有发展前景的早期生物技术的风险投资公司。Hibiscus拥有多年创建和投资生物技术公司的经验，由行业专家团队领导。这些专家可以带来必需的资源，成功开发满足患者需求的新疗法。

了解更多关于Hibiscus BioVentures的信息，请访问Hibiscus BioVentures website 和LinkedIn。

关于健新原力

健新原力聚焦于RNA、细胞和基因治疗制品领域，致力于为先进疗法药物合作伙伴提供包括质粒、病毒载体、细胞治疗产品、mRNA在内的一站式CDMO解决方案。健新原力团队在工艺开发、临床及商业化GMP生产、LNP包封和无菌灌装、项目管理及申报等领域拥有丰富经验，是您值得信赖的先进疗法合作伙伴。

Aug. 31, 2022， Mayo Clinic, Hibiscus BioVentures (Hibiscus) and Innoforce announce the launch of Mayflower BioVentures, a cell and gene therapy accelerator dedicated to identifying and forming companies around technologies that address unmet patient needs. This academic and industry relationship will establish independent cell and gene therapy companies to advance the development of Mayo Clinic technologies through preclinical and early feasibility studies.

With a shared interest in identifying treatments and preventing disease, the aim of Mayflower is to advance new cures for serious and complex conditions through cell and gene therapies.

Mayo Clinic, ranked as the No.1 hospital in the nation for the seventh year in a row by U.S. News & World Report, has generated a portfolio of next-generation immune system modulators and multiple novel therapeutics in cell and gene therapy. Mayo Clinic's Center for Regenerative Biotherapeutics is leading efforts to rapidly advance regenerative technologies from discovery into early phase clinical trials. This includes a focus on industry collaborations with companies such as Hibiscus that have resources to support and expedite this work.

"Mayo Clinic is committed to building an advanced ecosystem for the development, manufacture and delivery of next-generation therapeutics," says Julie Allickson, Ph.D., the Michael S. and Mary Sue Shannon Family Director of Mayo Clinic's Center for Regenerative Biotherapeutics. "Cell and gene therapies have the potential to provide a new era of biologic drugs that offer hope for people with conditions that have few or no therapeutic options. We are very excited to work with Hibiscus to speed the development of new biotherapeutics."

Dr. Allickson also is the Otto Bremer Trust Director, Biomanufacturing and Product Development in the Center for Regenerative Biotherapeutics.

"This collaboration with Mayo Clinic and Hibiscus provides a strong platform for accelerating the development of cell and gene therapies," says Ken Carter, Ph.D., Innoforce's president of U.S. operations. "We are excited to work with these two excellent organizations as we continue to establish partnered end-to-end solutions for advanced medicines."

"Our collaboration with Mayo Clinic represents a distinct research and industry coalition with a shared mission to create a powerful force for the advancement of cell and gene therapies," says Sia Anagnostou, chief operating officer of Hibiscus BioTechnology. "Together, we aim to provide a springboard for startups leveraging the research capabilities at Mayo Clinic with a focus on addressing significant unmet patient needs."

The Mayflower management team brings together clinical leaders from Mayo Clinic with operational and investment experience from Hibiscus to move scientific discoveries from the lab bench to patients' bedsides.

"We believe this collaboration can bridge the gap between industry and innovative cell and gene therapy research, enabling emerging startups to navigate the challenges of producing meaningful, novel therapeutics that transform health and medicine," says Andrew Danielsen, chair of Mayo Clinic Ventures.

Mayo Clinic, Hibiscus and Innoforce have a financial interest in the Mayflower collaboration. Mayo Clinic will use any revenue it receives to support its nonprofit mission in patient care, education and research.

About Mayo Clinic

Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.

About Mayo Clinic's Center for Regenerative Medicine

Mayo Clinic's Center for Regenerative Medicineseeks to integrate, develop and deploy new regenerative medicine products and services that continually differentiate Mayo's practice to draw patients from around the world for complex care. Learn more on Mayo Clinic's Center for Regenerative Medicine website.

About Hibiscus BioVentures

Hibiscus BioVentures (Hibiscus) is committed to advancing patient care by building patient-focused companies around transformative technologies and the development of commercially viable therapies. Hibiscus has "two sides of the house" — Hibiscus Biotechnology (HBT), LLC, a venture studio focused on building companies from the ground up — and Hibiscus Capital Management (HCM), LLC, a venture capital firm focused on investing in promising early stage biotechnology companies. Hibiscus brings years of experience building and investing in biotechnology companies and is led by a team of industry experts who can bring the resources necessary to successfully develop new therapies that address unmet patient needs.

Learn more about Hibiscus BioVentures on the Hibiscus BioVentures website and on LinkedIn.

About Innoforce

Innoforce is a partnership-focused biopharmaceutical company established to enable and accelerate the innovation of breakthrough ATMPs and Biologics. Innoforce offers end-to-end contract development and manufacturing service (CDMO), including GMP manufacturing of plasmid DNA, RNA, viral vector, and cell products. In addition, through a joint venture with a leading international supplier of life sciences products &and services, the company provides CDMO services for antibody and protein drugs. Innoforce’s capabilities for incubating and developing cell, gene, and advanced biological therapies companies to rapidly and efficiently bring cutting-edge treatments that impact patients' lives worldwide. More information is available at https://www.innoforcepharma.com/